A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.
Pharmaceutical firms' adept handling of patent expirations has boosted investors' opinions of the sector, says Morningstar's Damien Conover.
A new ROIC-focused process for compound development plus the value of Pfizer's other businesses add up to a fair value well in excess of $14, says RS Investments manager Joe Wolf.
Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover.
Good day everyone, and welcome to Pfizer s Third Quarter 2010 Earnings Conference Call. Today s call is being recorded.
Working with sports stars can be prestigious, even glamorous -- and is often a highly sought after market niche for financial advisors and wealth managers, but professional athletes can also present advisors with a minefield of challenges
©2012 Morningstar Advisor. All right reserved.